Skip to main content

Advertisement

SpringerLink
Log in

Sarcopenia and fatty liver disease

  • Review Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease which may progress to non-alcoholic steatohepatitis. The prevalence of sarcopenia, which is the loss of muscle mass and strength, is increasing in the aging society. Recent studies reported the relationship between NAFLD and sarcopenia. The skeletal muscle is the primary organ for glucose disposal. Loss of muscle mass can cause insulin resistance, which is an important risk factor for NAFLD. Moreover, obesity, chronic low-grade inflammation, vitamin D deficiency, physical inactivity, hepatokines, and myokines might be involved in the pathophysiologic mechanism of sarcopenia and NAFLD. Although most of the previous studies have demonstrated the positive correlation between sarcopenia and NAFLD, the difference in diagnostic methods of sarcopenia and NAFLD leads to difficulties in interpretation and application. This review discusses the concept and diagnosis of sarcopenia and NAFLD, common pathophysiology, and clinical studies linking sarcopenia to NAFLD. The presentation of the association between sarcopenia and NAFLD may provide an opportunity to prevent the deterioration of fatty liver disease.

Graphic abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12:249–56.

    PubMed  Google Scholar 

  2. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31.

    PubMed  Google Scholar 

  3. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S157–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.

    PubMed  Google Scholar 

  5. Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A guide to non-alcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci. 2016;17:947.

    PubMed Central  Google Scholar 

  6. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123–33.

    CAS  PubMed  Google Scholar 

  7. Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17:774.

    PubMed Central  Google Scholar 

  8. Pan X, Han Y, Zou T, Zhu G, Xu K, Zheng J, et al. Sarcopenia contributes to the progression of nonalcoholic fatty liver disease- related fibrosis: a meta-analysis. Dig Dis. 2018;36:427–36.

    PubMed  Google Scholar 

  9. Kim G, Kang SH, Kim MY, Baik SK. Prognostic value of sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis. PLoS One. 2017;12:e0186990.

    PubMed  PubMed Central  Google Scholar 

  10. Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis. 2007;11(105–117):ix.

    Google Scholar 

  11. Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13:509–20.

    CAS  PubMed  Google Scholar 

  12. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008;75:721–8.

    PubMed  Google Scholar 

  13. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–402.

    Google Scholar 

  14. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082–90.

    PubMed  Google Scholar 

  15. Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022–30.

    PubMed  Google Scholar 

  16. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462–8.

    CAS  PubMed  Google Scholar 

  17. Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7:313–24.

    PubMed  Google Scholar 

  18. Rosenberg IH. Summary comments. Am J Clin Nutr. 1989;50:1231–3.

    Google Scholar 

  19. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755–63.

    CAS  PubMed  Google Scholar 

  20. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39:412–23.

    PubMed  PubMed Central  Google Scholar 

  21. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014;15:95–101.

    PubMed  Google Scholar 

  22. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002;50:889–96.

    PubMed  Google Scholar 

  23. Lim S, Kim JH, Yoon JW, Kang SM, Choi SH, Park YJ, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean longitudinal study on health and aging (KLoSHA). Diabetes Care. 2010;33:1652–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69:547–58.

    PubMed  PubMed Central  Google Scholar 

  25. Kim TN, Park MS, Lee EJ, Chung HS, Yoo HJ, Kang HJ, et al. Comparisons of three different methods for defining sarcopenia: an aspect of cardiometabolic risk. Sci Rep. 2017;7:6491.

    PubMed  PubMed Central  Google Scholar 

  26. Heymsfield SB. Development of imaging methods to assess adiposity and metabolism. Int J Obes (Lond). 2008;32(Suppl 7):S76–82.

    CAS  Google Scholar 

  27. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629–35.

    PubMed  Google Scholar 

  28. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40:423–9.

    PubMed  Google Scholar 

  29. Leong DP, Teo KK, Rangarajan S, Lopez-Jaramillo P, Avezum A Jr, Orlandini A, et al. Prognostic value of grip strength: findings from the prospective urban rural epidemiology (PURE) study. Lancet. 2015;386:266–73.

    PubMed  Google Scholar 

  30. Kim HK, Suzuki T, Saito K, Yoshida H, Kobayashi H, Kato H, et al. Effects of Exercise and amino acid supplementation on body composition and physical function in community-dwelling elderly japanese sarcopenic women: a randomized controlled trial. J Am Geriatr Soc. 2012;60:16–23.

    PubMed  Google Scholar 

  31. Villareal DT, Aguirre L, Gurney AB, Waters DL, Sinacore DR, Colombo E, et al. Aerobic or Resistance exercise, or both, in dieting obese older adults. N Engl J Med. 2017;376:1943–55.

    PubMed  PubMed Central  Google Scholar 

  32. Hong HC, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology. 2014;59:1772–8.

    CAS  PubMed  Google Scholar 

  33. Lee YH, Jung KS, Kim SU, Yoon HJ, Yun YJ, Lee BW, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011). J Hepatol. 2015;63:486–93.

    PubMed  Google Scholar 

  34. Lee YH, Kim SU, Song K, Park JY, Kim DY, Ahn SH, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008–2011). Hepatology. 2016;63:776–86.

    CAS  PubMed  Google Scholar 

  35. Kim HY, Kim CW, Park CH, Choi JY, Han K, Merchant AT, et al. Low skeletal muscle mass is associated with non-alcoholic fatty liver disease in Korean adults: the Fifth Korea national health and nutrition examination survey. Hepatobiliary Pancreat Dis Int. 2016;15:39–47.

    PubMed  Google Scholar 

  36. Hashimoto Y, Osaka T, Fukuda T, Tanaka M, Yamazaki M, Fukui M. The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes. Endocr J. 2016;63:877–84.

    CAS  PubMed  Google Scholar 

  37. Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017;66:123–31.

    PubMed  Google Scholar 

  38. Kim G, Lee SE, Lee YB, Jun JE, Ahn J, Bae JC, et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study. Hepatology. 2018;68:1755–68.

    CAS  PubMed  Google Scholar 

  39. Lee MJ, Kim EH, Bae SJ, Kim GA, Park SW, Choe J, et al. Age-related decrease in skeletal muscle mass is an independent risk factor for incident nonalcoholic fatty liver disease: a 10-year retrospective cohort study. Gut Liver. 2019;13:67–76.

    PubMed  Google Scholar 

  40. Meng G, Wu H, Fang L, Li C, Yu F, Zhang Q, et al. Relationship between grip strength and newly diagnosed nonalcoholic fatty liver disease in a large-scale adult population. Sci Rep. 2016;6:33255.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Zhai Y, Xiao Q, Miao J. The relationship between NAFLD and sarcopenia in elderly patients. Can J Gastroenterol Hepatol. 2018;2018:5016091.

    PubMed  PubMed Central  Google Scholar 

  42. Kang MK, Park JG, Lee HJ, Kim MC. Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2019;34:1633–40.

    CAS  PubMed  Google Scholar 

  43. Issa D, Alkhouri N, Tsien C, Shah S, Lopez R, McCullough A, et al. Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis. Hepatology. 2014;60:428–9.

    PubMed  Google Scholar 

  44. Petta S, Ciminnisi S, Di Marco V, Cabibi D, Camma C, Licata A, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017;45:510–8.

    CAS  PubMed  Google Scholar 

  45. Wijarnpreecha K, Kim D, Raymond P, Scribani M, Ahmed A. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. Eur J Gastroenterol Hepatol. 2019;31:1121–8.

    CAS  PubMed  Google Scholar 

  46. Peng TC, Wu LW, Chen WL, Liaw FY, Chang YW, Kao TW. Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES III): the importance of sarcopenia definition. Clin Nutr. 2019;38:422–8.

    PubMed  Google Scholar 

  47. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.

    CAS  PubMed  Google Scholar 

  48. Fujita S, Rasmussen BB, Cadenas JG, Drummond MJ, Glynn EL, Sattler FR, et al. Aerobic exercise overcomes the age-related insulin resistance of muscle protein metabolism by improving endothelial function and Akt/mammalian target of rapamycin signaling. Diabetes. 2007;56:1615–22.

    CAS  PubMed  Google Scholar 

  49. Turcotte LP, Fisher JS. Skeletal muscle insulin resistance: roles of fatty acid metabolism and exercise. Phys Ther. 2008;88:1279–96.

    PubMed  PubMed Central  Google Scholar 

  50. Kim TN, Park MS, Yang SJ, Yoo HJ, Kang HJ, Song W, et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care. 2010;33:1497–9.

    PubMed  PubMed Central  Google Scholar 

  51. Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metab. 2007;5:237–52.

    CAS  PubMed  Google Scholar 

  52. Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA. 2007;104:12587–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510:84–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Kato K-I, Takeshita Y, Misu H, Zen Y, Kaneko S, Takamura T. Liver steatosis is associated with insulin resistance in skeletal muscle rather than in the liver in Japanese patients with non-alcoholic fatty liver disease. J Diabetes Investig. 2015;6:158–63.

    CAS  PubMed  Google Scholar 

  55. Kim TN, Park MS, Ryu JY, Choi HY, Hong HC, Yoo HJ, et al. Impact of visceral fat on skeletal muscle mass and vice versa in a prospective cohort study: the Korean Sarcopenic Obesity Study (KSOS). PLoS One. 2014;9:e115407.

    PubMed  PubMed Central  Google Scholar 

  56. Cha JY, Kim DH, Chun KH. The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Lab Anim Res. 2018;34:133–9.

    PubMed  PubMed Central  Google Scholar 

  57. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000;11:327–32.

    CAS  PubMed  Google Scholar 

  58. Polyzos SA, Kountouras J, Zavos C, Deretzi G. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J Clin Gastroenterol. 2011;45:50–4.

    CAS  PubMed  Google Scholar 

  59. Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia. 2016;59:30–43.

    CAS  PubMed  Google Scholar 

  60. Waters DL, Qualls CR, Dorin RI, Veldhuis JD, Baumgartner RN. Altered growth hormone, cortisol, and leptin secretion in healthy elderly persons with sarcopenia and mixed body composition phenotypes. J Gerontol A Biol Sci Med Sci. 2008;63:536–41.

    PubMed  Google Scholar 

  61. Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res. 2015;25:59–65.

    CAS  PubMed  Google Scholar 

  62. Poggiogalle E, Lubrano C, Gnessi L, Mariani S, Lenzi A, Donini LM. Fatty liver index associates with relative sarcopenia and GH/IGF-1 status in obese subjects. PLoS One. 2016;11:e0145811.

    PubMed  PubMed Central  Google Scholar 

  63. Kim TN, Won JC, Kim YJ, Lee EJ, Kim MK, Park MS, et al. Serum adipocyte fatty acid-binding protein levels are independently associated with sarcopenic obesity. Diabetes Res Clin Pract. 2013;101:210–7.

    CAS  PubMed  Google Scholar 

  64. Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KS, et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology. 2009;49:1926–34.

    CAS  PubMed  Google Scholar 

  65. Girgis CM, Clifton-Bligh RJ, Hamrick MW, Holick MF, Gunton JE. The roles of vitamin D in skeletal muscle: form, function, and metabolism. Endocr Rev. 2013;34:33–83.

    CAS  PubMed  Google Scholar 

  66. Dzik KP, Kaczor JJ. Mechanisms of vitamin D on skeletal muscle function: oxidative stress, energy metabolism and anabolic state. Eur J Appl Physiol. 2019;119:825–39.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Visser M, Deeg DJ, Lips P. Longitudinal Aging study amsterdam. low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the longitudinal aging study amsterdam. J Clin Endocrinol Metab. 2003;88:5766–72.

    CAS  PubMed  Google Scholar 

  68. Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut. 2011;60:1728–37.

    CAS  PubMed  Google Scholar 

  69. Zhai HL, Wang NJ, Han B, Li Q, Chen Y, Zhu CF, et al. Low vitamin D levels and non-alcoholic fatty liver disease, evidence for their independent association in men in East China: a cross-sectional study (Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (SPECT-China)). Br J Nutr. 2016;115:1352–9.

    CAS  PubMed  Google Scholar 

  70. Eliades M, Spyrou E, Agrawal N, Lazo M, Brancati FL, Potter JJ, et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38:246–54.

    CAS  PubMed  Google Scholar 

  71. Nelson JE, Roth CL, Wilson LA, Yates KP, Aouizerat B, Morgan-Stevenson V, et al. Vitamin D Deficiency is associated with increased risk of non-alcoholic steatohepatitis in adults with non-alcoholic fatty liver Disease: possible role for MAPK and NF-kappaB? Am J Gastroenterol. 2016;111:852–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Patel YA, Henao R, Moylan CA, Guy CD, Piercy DL, Diehl AM, et al. Vitamin D is not associated with severity in NAFLD: results of a paired clinical and gene expression profile analysis. Am J Gastroenterol. 2016;111:1591–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Engin A. Non-alcoholic fatty liver disease. Adv Exp Med Biol. 2017;960:443–67.

    CAS  PubMed  Google Scholar 

  74. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46–54.

    CAS  PubMed  Google Scholar 

  75. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103:1372–9.

    CAS  PubMed  Google Scholar 

  76. Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002;57:M326–32.

    PubMed  Google Scholar 

  77. Baylis D, Bartlett DB, Syddall HE, Ntani G, Gale CR, Cooper C, et al. Immune-endocrine biomarkers as predictors of frailty and mortality: a 10-year longitudinal study in community-dwelling older people. Age (Dordr). 2013;35:963–71.

    CAS  Google Scholar 

  78. Camporez JP, Jornayvaz FR, Petersen MC, Pesta D, Guigni BA, Serr J, et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology. 2013;154:3099–109.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58:250–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Lan F, Misu H, Chikamoto K, Takayama H, Kikuchi A, Mohri K, et al. LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance. Diabetes. 2014;63:1649–64.

    CAS  PubMed  Google Scholar 

  81. Yoo HJ, Hwang SY, Choi JH, Lee HJ, Chung HS, Seo JA, et al. Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis. PLoS One. 2017;12:e0174717.

    PubMed  PubMed Central  Google Scholar 

  82. Hara H, Uchida S, Yoshimura H, Aoki M, Toyoda Y, Sakai Y, et al. Isolation and characterization of a novel liver-specific gene, hepassocin, upregulated during liver regeneration. Biochim Biophys Acta. 2000;1492:31–44.

    CAS  PubMed  Google Scholar 

  83. Wu HT, Lu FH, Ou HY, Su YC, Hung HC, Wu JS, et al. The role of hepassocin in the development of non-alcoholic fatty liver disease. J Hepatol. 2013;59:1065–72.

    CAS  PubMed  Google Scholar 

  84. Wu HT, Ou HY, Hung HC, Su YC, Lu FH, Wu JS, et al. A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes. Diabetologia. 2016;59:1732–42.

    CAS  PubMed  Google Scholar 

  85. Jung TW, Chung YH, Kim HC, Abd El-Aty AM, Jeong JH. Hyperlipidemia-induced hepassocin in the liver contributes to insulin resistance in skeletal muscle. Mol Cell Endocrinol. 2018;470:26–33.

    CAS  PubMed  Google Scholar 

  86. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463–8.

    PubMed  PubMed Central  Google Scholar 

  87. Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS. Irisin in patients with nonalcoholic fatty liver disease. Metabolism. 2014;63:207–17.

    CAS  PubMed  Google Scholar 

  88. Zhang HJ, Zhang XF, Ma ZM, Pan LL, Chen Z, Han HW, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol. 2013;59:557–62.

    CAS  PubMed  Google Scholar 

  89. Choi HY, Kim S, Park JW, Lee NS, Hwang SY, Huh JY, et al. Implication of circulating irisin levels with brown adipose tissue and sarcopenia in humans. J Clin Endocrinol Metab. 2014;99:2778–85.

    CAS  PubMed  Google Scholar 

  90. Chang JS, Kim TH, Nguyen TT, Park KS, Kim N, Kong ID. Circulating irisin levels as a predictive biomarker for sarcopenia: a cross-sectional community-based study. Geriatr Gerontol Int. 2017;17:2266–73.

    PubMed  Google Scholar 

  91. Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011;2:143–51.

    PubMed  PubMed Central  Google Scholar 

  92. Wilkes JJ, Lloyd DJ, Gekakis N. Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance. Diabetes. 2009;58:1133–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Steffl M, Bohannon RW, Sontakova L, Tufano JJ, Shiells K, Holmerova I. Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging. 2017;12:835–45.

    PubMed  PubMed Central  Google Scholar 

  94. Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology. 2009;50:1105–12.

    CAS  PubMed  Google Scholar 

  95. Garatachea N, Lucía A. Genes and the ageing muscle: a review on genetic association studies. Age. 2013;35:207–33.

    CAS  PubMed  Google Scholar 

  96. Jones G, Pilling LC, Kuo CL, Kuchel G, Ferrucci L, Melzer D. Sarcopenia and variation in the human leukocyte antigen complex. J Gerontol A Biol Sci Med Sci. 2019. https://doi.org/10.1093/gerona/glz042.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68:268–79.

    CAS  PubMed  Google Scholar 

  98. Franko A, Merkel D, Kovarova M, Hoene M, Jaghutriz BA, Heni M, et al. Dissociation of fatty liver and insulin resistance in I148 M PNPLA3 carriers: differences in diacylglycerol (DAG) FA18:1 lipid species as a possible explanation. Nutrients. 2018;10:1314.

    PubMed Central  Google Scholar 

  99. Palmer CN, Maglio C, Pirazzi C, Burza MA, Adiels M, Burch L, et al. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148 M variant. PLoS One. 2012;7:e39362.

    CAS  PubMed  PubMed Central  Google Scholar 

  100. Jegatheesan P, De Bandt J-P. Fructose and NAFLD: the multifaceted aspects of fructose metabolism. Nutrients. 2017;9:230.

    PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported in part by a grant of Korea University.

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Korea University Guro Hospital, 148 Guro-Dong, Guro-Gu, Seoul, 08308, South Korea

    Jung A. Kim & Kyung Mook Choi

Authors
  1. Jung A. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kyung Mook Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kyung Mook Choi.

Ethics declarations

Conflict of interest

Jung A. Kim and Kyung Mook Choi have no conflicts of interest to disclose.

Ethical approval

This article does not contain any studies with human or animal subjects.

Informed consent

Informed consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, J.A., Choi, K.M. Sarcopenia and fatty liver disease. Hepatol Int 13, 674–687 (2019). https://doi.org/10.1007/s12072-019-09996-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-019-09996-7

Keywords

Search

Navigation